The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives using an aqueous nasal administration. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism.

The present invention relates to the use of a starch nanoparticle loaded with at least one active molecule of interest to feed zooplankton, in particular a living prey chosen from rotifers, brine shrimp and copepods. In particular, the invention relates to the use of this loaded starch nanoparticle to increase the size and/or density and/or egg-laying rate of this zooplankton, and/or the hatching rate of the eggs thereof

The present invention relates to the use of a starch nanoparticle loaded with at least one active molecule of interest to feed zooplankton, in particular a living prey chosen from rotifers, brine shrimp and copepods. In particular, the invention relates to the use of this loaded starch nanoparticle to increase the size and/or density and/or egg-laying rate of this zooplankton, and/or the hatching rate of the eggs thereof

Provided herein are methods and compositions relating to modified proteins of Anti-Müllerian hormone (AMH) for regulating folliculogenesis in a woman, and in particular regulating follicle activation and maturation and immature (primordial) follicle depletion. In certain embodiments, regulating or inhibiting folliculogenesis in a woman treats ovarian senescence, pauses or slows down ovarian aging and/or delays the onset of menopause and/or the symptoms related to menopause, premature ovarian decline induced by gonadotoxic treatment, or diseases or conditions caused by genetic mutations in genes regulating folliculogenesis and ovarian biology.

Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.

The invention relates to a method for detecting residual, undifferentiated pluripotent stem cells (PSCs) in a culture of cells differentiated from PSCs, the method comprising: culturing the cells on a substrate coated with laminin-521 and E-cadherin in a medium comprising a ROCK inhibitor; quantitating in the cultured cells expression of a marker of residual, undifferentiated PSCs; and comparing the marker expression in the cultured cells with the marker expression in a reference culture of cells comprising a known proportion of PSCs, wherein lower marker expression in the culture of cells than marker expression in the reference culture of cells indicates absence of residual, undifferentiated PSCs in the cultured cells or presence of residual, undifferentiated PSCs in the cultured cells at a proportion lower than the known proportion of PSCs in the reference culture of cells. The invention also relates to a method for manufacturing a therapeutic composition and a method for treating or preventing a condition in a subject.

Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.

Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

The present invention relates to injectable microspheres and formulations comprising the microspheres for controlled release of progestogen hormones.

Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.